pmjТихоокеанский медицинский журналPacific Medical Journal1609-1175TGMU10.34215/1609-1175-2022-3-91-95pmj-2369Research ArticleНАБЛЮДЕНИЯ ИЗ ПРАКТИКИPRACTICE OBSERVATIONSПрименение нового антивазопролиферативного препарата в лечении экссудативной возрастной макулярной дегенерацииA new antiproliferative drug for exudative age-related macular degenerationРукинаД. А.RukinaD. A.

Владивосток

Vladivostok

https://orcid.org/0000-0003-0150-0915ПестряковаЯ. Ф.PestryakovaYa. F.

канд. мед. наук, главный врач,

690106, г. Владивосток, Партизанский пр., 44

Chief of Eye Center,

44, Partizansky Ave., Vladivostok, 690106

pestrikova75@mail.ruМирошниченкоО. В.MiroshnichenkoO. V.

Владивосток

Vladivostok

УстюговаС. О.UstyugovaS. O.

Владивосток

Vladivostok

Глазной центрРоссияEye CenterRussian FederationДальневосточный федеральный университетРоссияFar Eastern Federal UniversityRussian FederationТихоокеанский государственный медицинский университетРоссияPacific State Medical UniversityRussian Federation202208092022039195Copyright © Рукина Д.А., Пестрякова Я.Ф., Мирошниченко О.В., Устюгова С.О., 20222022Рукина Д.А., Пестрякова Я.Ф., Мирошниченко О.В., Устюгова С.О.Rukina D.A., Pestryakova Y.F., Miroshnichenko O.V., Ustyugova S.O.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.tmj-vgmu.ru/jour/article/view/2369

Возрастная макулярная дегенерация (ВМД) сетчатки – одна из основных причин необратимого снижения зрения среди лиц старшей возрастной группы, в связи с чем является серьезной проблемой современности. В последние два десятилетия в лечении ВМД успешно применяются ингибиторы фактора роста эндотелия сосудов (анти-VEGF). Данная работа посвящена изучению нового антивазопролиферативного препарата бролуцизумаб (Визкью) при влажной форме ВМД. Препарат продемонстрировал высокую эффективность по быстроте наступления терапевтического эффекта, достижению разрешения интраретинальной и субретинальной экссудации. 

Age-related macular degeneration (AMD) is one of the major reasons that cause irreversible vision loss among older people. Over the past two decades, vascular endothelial growth factor (anti-VEGF) inhibitors have been successfully used in the treatment of AMD. In this article, we study a new antivasoproliferative agent brolucizumab for the treatment of exudative AMD forms. The drug has demonstrated its high effectiveness in terms of a more rapid onset of therapeutic effect and the resolution of intraretinal and subretinal exudation. 

возрастная макулярная дегенерацияинтравитреальные инъекциибролуцизумабинтраретинальнаясубретинальная жидкостьage-related macular degenerationintravitreal injectionsbrolucizumabintraretinalsubretinal fluidReferencesWang D, Jiang Y, He M, Scheetz J, Wang W. Disparities in the Global Burden of Age-Related Macular Degeneration: An Analysis of Trends from 1990 to 2015. Curr Eye Res. 2019;44(6):657–63. doi: 10.1080/02713683.2019.1576907Wang D, Jiang Y, He M, Scheetz J, Wang W. Disparities in the Global Burden of Age-Related Macular Degeneration: An Analysis of Trends from 1990 to 2015. Curr Eye Res. 2019;44(6):657–63. doi: 10.1080/02713683.2019.1576907Оганезова Ж.Г. Возрастная макулярная дегенерация: новое средство для профилактики и лечения. Клиническая офтальмология. 2013;14(3):130–5.Oganezova JG. A new drug for treatment and prophylaxis of age-related macular degeneration. Russian Journal of Clinical Ophthalmology. 2013;14(3):130– 5 (In Russ.)Wong WL, Su X, Li X, Cheung CM, Klein R, Cheng CY, Wong TY. Global prevalence of age-related macular degeneration and disease burden projection for 2020 and 2040: a systematic review and meta-analysis. Lancet Glob Health. 2014;2(2):106–16. doi: 10.1016/S2214-109X(13)70145-1Wong WL, Su X, Li X, Cheung CM, Klein R, Cheng CY, Wong TY. Global prevalence of age-related macular degeneration and disease burden projection for 2020 and 2040: a systematic review and meta-analysis. Lancet Glob Health. 2014;2(2):106–16. doi: 10.1016/S2214-109X(13)70145-1Будзинская М.В., Плюхова А.А. Перспективы антиангиогенной терапии при заболеваниях сетчатки. Офтальмология. 2021;18(3S):638–45.Budzinskaya MV, Pluhova AA. Prospects of antiangiogenic therapy in retinal diseases. Ophthalmology. 2021;18(3S):638–45 (In Russ.)Королева И.А., Гветадзе А.А., Романова Т.Б. Фармакотерапия ВМД: обзор новых тенденций. Клиническая Офтальмология. 2019;2:105–9. doi: 10.32364/2311-7729-2019-19-2-105-109. URL: https://www.rmj.ru/articles/oftalmologiya/Farmakoterapiya_VMD_obzor_novyh_tendenciy/#ixzz7NfohCUNz (In Russ.)]Koroleva IA, Gvetadze AA, Romanova TB. Pharmacotherapy of AMD: overview of new trends. Clin. Ophthalmol. 2019;2:105–9. URL: https://www.rmj.ru/articles/oftalmologiya/Farmakoterapiya_VMD_obzor_novyh_tendenciy/#ixzz7NfohCUNz (In Russ.)] doi: 10.32364/2311-7729-2019-19-2-105-109.Tadayoni R, Sararols L, Weissgerber G, Verma R, Clemens A. Brolucizumab: a newly developed anti-VEGF molecule for the treatment of Neovascular Age-Related Macular Degeneration. Ophthalmologica, 2021, 244:93–101. doi: 10.1159/000513048Tadayoni R, Sararols L, Weissgerber G, Verma R, Clemens A. Brolucizumab: a newly developed anti-VEGF molecule for the treatment of Neovascular Age-Related Macular Degeneration. Ophthalmologica, 2021, 244:93–101. doi: 10.1159/000513048Dugel PU, Jaffe GJ, Sallstig P, Warburton J, Weichselberg A. Brolucizumab versus Aflibercept in participants with neovascular age-related macular degeneration: a randomized trial. American Academy of Ophthalmology. 2017;3:1–9. doi: 10/2016/j.ophtha.2017.03.057Dugel PU, Jaffe GJ, Sallstig P, Warburton J, Weichselberg A. Brolucizumab versus Aflibercept in participants with neovascular age-related macular degeneration: a randomized trial. American Academy of Ophthalmology. 2017;3:1–9. doi: 10/2016/j.ophtha.2017.03.057Hussan RM, Ntal A, Yanussi NA, Patel KH, Huo S. Brolucizumab for persistant macular fluid in neovascular age-related macular degeneration after prior anti-VEGF tretments. Therapeutic Advances in Ophthalmology. 2021;13:1–10. doi: 10.1177/25158414211055964Hussan RM, Ntal A, Yanussi NA, Patel KH, Huo S. Brolucizumab for persistant macular fluid in neovascular age-related macular degeneration after prior anti-VEGF tretments. Therapeutic Advances in Ophthalmology. 2021;13:1–10. doi: 10.1177/25158414211055964Haensli C, Pfister IB, Garweg JG. Switching to Brolucizumab in Neovascular Age-Related Macular Degeneration Incompletely Responsive to Ranibizumab or Aflibercept: Real-Life 6 Month Outcomes. J. Clin. Med. 2021;10:2666. doi: 10.3390/jcm10122666Haensli C, Pfister IB, Garweg JG. Switching to Brolucizumab in Neovascular Age-Related Macular Degeneration Incompletely Responsive to Ranibizumab or Aflibercept: Real-Life 6 Month Outcomes. J. Clin. Med. 2021;10:2666. doi: 10.3390/jcm10122666Fukuda Y, Sakurada Y, Matsubara M, Hasebe Y, Sugiyama A, Kikushima W. Comparison of outcomes between 3 monthly Brolucizumab and Aflibercept injections for Polypoidal Choroidal Vasculopathy. Biomedicines. 2021;9:1164. doi: 10.3390/biomedicines9091164Fukuda Y, Sakurada Y, Matsubara M, Hasebe Y, Sugiyama A, Kikushima W. Comparison of outcomes between 3 monthly Brolucizumab and Aflibercept injections for Polypoidal Choroidal Vasculopathy. Biomedicines. 2021;9:1164. doi: 10.3390/biomedicines9091164Montesel A, Bucolo C, Sallo FB, Eandi CM. Short-term efficacy and safety outcomes of Brolucizumab in the real-life clinical practice. Frontiers in Pharmacology. 2021;12. doi: 10.3389/fphar2021.720345Montesel A, Bucolo C, Sallo FB, Eandi CM. Short-term efficacy and safety outcomes of Brolucizumab in the real-life clinical practice. Frontiers in Pharmacology. 2021;12. doi: 10.3389/fphar2021.720345Baumal CR, Spaide RF, Vajzomic L, Bailey Freund K, Walter SD, John V, Rich R, Chaudhry N, Lakhanpal RR. Retinal Vasculitis and intraocular inflammation after intravitreal injection of Brolucizumab. Ophthalmology. 2020;127(10):1345–59. doi: 10.1016/j.ophtha.2020.04.017Baumal CR, Spaide RF, Vajzomic L, Bailey Freund K, Walter SD, John V, Rich R, Chaudhry N, Lakhanpal RR. Retinal Vasculitis and intraocular inflammation after intravitreal injection of Brolucizumab. Ophthalmology. 2020;127(10):1345–59. doi: 10.1016/j.ophtha.2020.04.017

The authors declare that there are no conflicts of interest present.